United States Patent 10,624,918: Scope, Claim Architecture, and US Acne-Topical Patent Landscape
US Drug Patent 10,624,918 claims a once-daily (up to 12 weeks) aqueous gel for acne combining benzoyl peroxide (2%-3.5% w/w) and clindamycin phosphate (1.2% w/w), with a specific stability architecture for benzoyl peroxide particles and a defined solvent balance using propylene glycol under narrow ratio constraints.
Because the operative text you provided includes the full independent claim structure and dependent limitations, the scope below is mapped directly to claim elements, with infringement-relevant “musts” and “may” toggles. The patent landscape assessment is built around the claim’s distinguishing technical constraints: particle size + saturated benzoyl peroxide solution + propylene glycol at defined multipliers + water:propylene glycol ratios + surfactant status.
What does claim 1 require, line-by-line?
What is the core treatment method?
Claim 1 requires a method for treating acne comprising:
- Dosage frequency and duration: “applying once a day for up to 12 weeks”
- Route and substrate: “to the skin of a patient in need thereof”
- Formulation type: an aqueous gel formulation containing:
- Water
- Water-miscible organic solvent comprising propylene glycol
- 2%-3.5% w/w benzoyl peroxide
- 1.2% w/w clindamycin phosphate
- A gelling agent
- Key stability and dispersion constraint (benzoyl peroxide state):
- formulation comprises a “stable suspension of benzoyl peroxide in a saturated solution of benzoyl peroxide”
- Key particle constraint:
- “benzoyl peroxide has a mean particle size of less than 100 microns”
- Key propylene glycol constraint (relative amount):
- concentration of propylene glycol is “between one and four times the concentration of benzoyl peroxide”
- Key solvent balance constraint (water:propylene glycol):
- “ratio of water to propylene glycol is at least 12:1”
What are the infringement “hard gates” in claim 1?
For a product to fall within claim 1, it must satisfy all of the following simultaneously:
- Combination actives and exact ranges
- Benzoyl peroxide: 2% to 3.5% w/w
- Clindamycin phosphate: 1.2% w/w
- Aqueous gel format
- Must be a “gel formulation” (gelling agent required)
- Application regimen
- once daily and “up to 12 weeks”
- Specific benzoyl peroxide dispersion state
- “stable suspension of benzoyl peroxide” in a saturated solution of benzoyl peroxide
- Benzoyl peroxide particle size
- mean particle size < 100 microns
- Propylene glycol function and amount
- propylene glycol is the water-miscible organic solvent component
- propylene glycol is 1x to 4x benzoyl peroxide concentration (by the claim’s “between one and four times” formulation)
- Water dominance
- water:propylene glycol >= 12:1
If any one of these gates is missed, claim 1 does not read.
What do dependent claims narrow?
How does claim 2 narrow propylene glycol loading?
- Propylene glycol concentration = 2x benzoyl peroxide concentration.
How does claim 3 narrow water:propylene glycol ratio?
- Water:propylene glycol ratio >= 17.5:1.
How does claim 4 limit the gelling agent?
- Gelling agent is a carboxyvinyl polymer.
How does claim 5 list specific cellulosics?
- Gelling agent is hydroxypropylcellulose OR hydroxyethylcellulose OR hydroxypropylmethyl cellulose.
How does claim 6 narrow benzoyl peroxide particle size?
- Mean particle size 2.5 to 30 microns (a tighter sub-range inside “<100 microns” of claim 1).
How does claim 7 treat clindamycin phosphate form?
- Clindamycin phosphate is dissolved in the formulation (rather than suspended).
How do claims 8 and 9 create an ambiguity-and-opportunity split on surfactants?
- Claim 8: formulation is free of surfactant
- Claim 9: formulation contains a surfactant
This pair is significant for the landscape because the claim set is structured to cover both positions on surfactant presence. That does not mean any surfactant type is acceptable, but it means surfactant is not a dispositive “avoidance” lever.
How does claim 10 broaden application sites?
- Application to: face, neck, back, and chest.
This matters for design-around because some acne products restrict labeling or studied application sites. Claim 10 reads on “expanded area use” within the same formulation.
Claim coverage map: “design-in” versus “design-around”
What is the protected subject matter at the formulation level?
The protected construct is not just “benzoyl peroxide + clindamycin phosphate in a gel.” It is that combination within an aqueous gel that satisfies the stability and solvent balance architecture.
| Element |
Claim 1 Scope |
Dependent Narrowing |
Practical relevance |
| Benzoyl peroxide % |
2% to 3.5% w/w |
none |
Drives “right strength” barrier for generic/alternative formulations |
| Clindamycin phosphate % |
1.2% w/w |
none |
Fixed loading requirement |
| Form |
aqueous gel + gelling agent |
gelling agent types limited in claims 4-5 |
Gels only; not lotion/cream/foam |
| Benzoyl peroxide state |
stable suspension in saturated benzoyl peroxide solution |
none |
A strong distinguishable technical feature |
| Benzoyl peroxide mean particle size |
< 100 microns |
2.5-30 microns in claim 6 |
Particle sizing can be a key lever |
| Propylene glycol content |
1x to 4x benzoyl peroxide concentration |
2x in claim 2 |
Solvent balance can be measured |
| Water:propylene glycol ratio |
>= 12:1 |
>= 17.5:1 in claim 3 |
Limits co-solvent-rich gels |
| Clindamycin state |
dissolved |
none (claim 7) |
Affects formulation categorization |
| Surfactant |
can be free or present |
claims 8-9 |
Presence alone may not avoid scope |
| Regimen |
once daily, up to 12 weeks |
none |
Dosing schedule can be a weak/strong lever depending on labels |
| Sites |
skin; claim 10 adds face/neck/back/chest |
claim 10 |
Label and studied instructions matter for claim 10 |
What design-around levers remain plausible from the claim text?
Based strictly on claim structure, the strongest “avoidance” levers are:
- Fail the benzoyl peroxide particle-size constraint (avoid “mean particle size <100 microns,” and if targeting narrower claim 6, avoid 2.5-30 microns).
- Break the propylene glycol constraint:
- propylene glycol not between 1x and 4x benzoyl peroxide concentration, or
- water:propylene glycol ratio below 12:1 (or 17.5:1 for claim 3).
- Break the saturated-suspension construct:
- the formulation is not a stable suspension of benzoyl peroxide in a saturated benzoyl peroxide solution.
- Change the actives concentration:
- benzoyl peroxide not within 2%-3.5% w/w, or clindamycin not at 1.2% w/w.
- Change gel type or remove required gelling agent class:
- if practicing outside “aqueous gel” with an appropriate gelling system.
- Change application regimen:
- not once daily or not “up to 12 weeks” (wording issues can arise in method claims, but the claim text is explicit).
Surfactant presence is not a reliable escape hatch because dependent claims expressly cover both “free of surfactant” and “contains a surfactant.”
What does this mean for the patent landscape?
How to interpret the patent’s positioning
The claim set is structured around a combination product concept using benzoyl peroxide + clindamycin phosphate, with a solvent/polymodal dispersion strategy. The differentiator is the benzoyl peroxide stability architecture: “stable suspension” inside a saturated benzoyl peroxide solution, plus a fine particle size ceiling and specific propylene glycol/water ratios.
In the US acne topical landscape, this typically maps to two competitive clusters:
- Fixed-dose combination gels/creams with actives and general gel carriers
- Formulation-technology patents that protect physical stability, particle engineering, and solvent/gelling-agent systems for benzoyl peroxide-containing combination topicals
This patent’s claim emphasis belongs to cluster #2 but anchors it to cluster #1’s clinical combination and dosing.
Which competitors and product archetypes are most “claim-close”
Even without external bibliographic lookup, the structure suggests claim adjacency to:
- Topical acne products combining clindamycin with benzoyl peroxide
- Formulations that use propylene glycol as a co-solvent
- Products that have benzoyl peroxide in a gel with engineered particle sizes
- Products whose benzoyl peroxide is stabilized in a way that could be characterized as a suspension in a saturated benzoyl peroxide environment
The risk to competitors is highest when they match all of the following at once:
- actives and concentration
- gel format
- benzoyl peroxide particle size below 100 microns
- propylene glycol balance within the 1x to 4x window and water:propylene glycol >=12:1
- stability language satisfied in manufacturing/process characterization (even if not explicitly disclosed on labels)
What is the practical scope of “surfactant” coverage
Because dependent claims 8 and 9 split surfactant status, the patent likely anticipates surfactant variability in commercial gel systems. Competitors cannot rely on “surfactant-free” or “surfactant-containing” status as a clear non-infringement path if the rest of claim 1 is met.
Method-of-use impact on labeling and instructions
Claim 10’s application sites matter in enforcement against “label-matching” products. If a competitor’s labeled instruction omits one or more of face/neck/back/chest, they may argue non-practice of the method as claimed. But claim 1 itself is “to the skin of a patient,” which is broader than claim 10. So label arguments likely only meaningfully differentiate if a court reads site limitations strictly through claim selection (claim 10 only).
Litigation and freedom-to-operate framing (from claim text)
What would an infringement analysis prioritize first?
For a candidate accused product, the top evidence buckets are:
- Quantitative formulation
- benzoyl peroxide % w/w
- clindamycin phosphate % w/w
- Physical form characterization
- benzoyl peroxide mean particle size (method and measurement)
- whether the formulation is a “stable suspension in a saturated benzoyl peroxide solution”
- Co-solvent system
- propylene glycol concentration
- water content
- compute water:propylene glycol ratio and propylene glycol/benzoyl peroxide multiplier
- Carrier and gelling agent
- whether it is a gel with an appropriate gelling agent
- Use regimen
- once daily dosing in practice and instructions
- duration “up to 12 weeks”
- Clindamycin form
- whether clindamycin phosphate is dissolved (for claim 7 relevance)
Where non-infringement arguments are likely to concentrate
From the claim text, the most persuasive non-infringement arguments are tied to:
- particle size not in range,
- propylene glycol and water ratio outside boundaries,
- failure to meet the saturated benzoyl peroxide suspension condition,
- actives concentration outside claim windows.
Key Takeaways
- US 10,624,918 protects a once-daily (up to 12 weeks) aqueous acne gel containing benzoyl peroxide 2%-3.5% w/w and clindamycin phosphate 1.2% w/w.
- The claim’s technical center of gravity is benzoyl peroxide stability: a stable suspension of benzoyl peroxide in a saturated benzoyl peroxide solution, with mean particle size <100 microns.
- The solvent system is constrained: propylene glycol = 1x to 4x benzoyl peroxide concentration, and water:propylene glycol >=12:1 (with dependent narrowing to >=17.5:1 and propylene glycol = 2x).
- Surfactant presence is not an escape route because dependent claims cover both surfactant-free and surfactant-containing formulations.
- The landscape risk concentrates on competitors whose acne combo gels also match the particle/solvent-stability engineering, not merely the actives combination.
FAQs
1) Does the patent cover acne treatment beyond gel application to the face/neck/back/chest?
Claim 1 covers application to the skin broadly. Claim 10 further specifies face, neck, back, and chest but is dependent, not exclusive.
2) Can a competitor avoid infringement by making the product surfactant-free?
No. Dependent claims explicitly include both surfactant-free (claim 8) and surfactant-containing (claim 9) embodiments.
3) Is the particle size requirement only “less than 100 microns,” or does the patent also claim a tighter range?
Claim 1 requires mean particle size <100 microns. Claim 6 narrows to 2.5 to 30 microns.
4) Are the propylene glycol and water ratios flexible?
No. Claim 1 requires propyl ene glycol at 1x to 4x benzoyl peroxide concentration and water:propylene glycol >=12:1. Dependent claims narrow to 2x and >=17.5:1.
5) What is the most technically critical element for a freedom-to-operate review?
The benzoyl peroxide stability construct: “stable suspension of benzoyl peroxide in a saturated solution of benzoyl peroxide,” plus the associated particle size constraint.
References
- United States Patent No. 10,624,918 (claim text provided by user).
